Dr. Xiaoming Xie is Surgeon and Chairman of the Department of Breast Oncology and Director of the Laboratory of Cancer Biotechnology in the State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center. Dr. Xie obtained his M.D. in 1986 and his Ph.D. in 1994 from Central South University. He later got postdoctoral training at the University of Navarra in Spain and University of Florida in USA. Dr.Xie worked as Research Associate in the Department of Immunology, Baylor College of Medicine, Houston, Texas, USA, during 1999 to 2003.

Since 2003, Dr. Xie became Research Scientist and Translational Group Leader at the University of Texas MD Anderson Cancer Center, Texas. Dr. Xie has gained multiple awards including the AstraZeneca Award, USA (2005), the Best Prize of the 10th Annual Oncology Research Seminar. USA (2001), the Travel Grant of the 6th Conference on retroviruses and Opportunistic Infections, USA (1999) and the Best Oral Presentation Award of Terapia genica del hepatocarcinoma mediate la transferencia del gen la interlukina 12 y timidin kinasa mediada por adenovirus.Madrid, Spain (1998) as well as Dr. Sir Q.W. Lee fellowship. USA (1997).

In 2008, he founded the Department of Breast Oncology in Sun Yat-sen University Cancer Center, Guangzhou, where he serves as the Chairman, Surgeon and Professor. His major research interests are targeted biotherapy for cancer, novel animal models for in vivo imaging, nanoparticle biotechnology, mechanism of development, metastasis and recurrence of breast cancer and basic and clinical research and clinical trial of breast cancer and clinical services (surgery and medical oncology).

Dr. Xiaoming Xie has published more than 60 peer-reviewed articles (including Nature Cell Biology, Cancer Cell, Cancer Research) with 11 patents and 3 ongoing clinical trials at MD Anderson Cancer Center. He is specialized in multidisciplinary care of breast cancer and translational research and clinical trials, as well as the primary investigator and co-investigator of more than 20 ongoing research projects and clinical trails supported by various grants.

1. Molecular biology of breast cancer/stem cells

2. Living imaging animal models of breast cancer /stem cells

3. Early diagnosis and biomarkers of breast cancer4. Nanoparticle-based targeted therapy

1981 - 1986 MD, Central South University Xiangya Medical College ( Faculty of Medicine, Hunan Medical University)

1990 – 1994 Ph.D., Molecular Virology and Oncology, Department of Internal medicine, Central South University Xiangya Medical College (Hunan Medical University)

Selected publications

1. Xie, X., Xia, W., Li, Z., Kuo, H-P.,Liu, Y., Li, Z., Ding, Q., Zhang, S., Spohn, W., Yang, Y., Wei, Y., Lang, J-Y., Evans, D.B., Chiao, P.J., Abbruzzese J.L. and Hung, M-C. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell, 2007;12(July10):52-65. (IF: 26.925).

2. Li L, Xie X, Luo J, Wei W , Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Yang M, Hung MC, X Xie (). Targeted Expression of miR-34a by T-VISA System Suppresses Tumor Cell Growth and Invasion in Breast Cancer. Mol Therapy; 2012; 20(12):2326-2334 (IF:6.873)

3. Xie X, L Li, X Xiao, J Guo, Y Kong, M Wu, W Liu, G Gao, J L. Hsu, W Wei, M-C Hung () and X Xie(). Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther.2012 ;11(9);1915-1924. (IF:5.226)

Last updated on: 2012